Literature DB >> 25175795

Eosinophils from hematopoietic stem cell recipients suppress allogeneic T cell proliferation.

Jennie Andersson1, Julia Cromvik2, Madeleine Ingelsten3, Christine Lingblom3, Kerstin Andersson3, Jan-Erik Johansson2, Christine Wennerås3.   

Abstract

Eosinophilia has been associated with less severe graft-versus-host disease (GVHD), but the underlying mechanism is unknown. We hypothesized that eosinophils diminish allogeneic T cell activation in patients with chronic GVHD. The capacity of eosinophils derived from healthy subjects and hematopoietic stem cell (HSC) transplant recipients, with or without chronic GVHD, to reduce allogeneic T cell proliferation was evaluated using a mixed leukocyte reaction. Eosinophil-mediated inhibition of proliferation was observed for the eosinophils of both healthy subjects and patients who underwent HSC transplantation. Eosinophils from patients with and without chronic GVHD were equally suppressive. Healthy eosinophils required cell-to-cell contact for their suppressive capacity, which was directed against CD4(+) T cells and CD8(+) T cells. Neither eosinophilic cationic protein, eosinophil-derived neurotoxin, indoleamine 2,3-dioxygenase, or increased numbers of regulatory T cells could account for the suppressive effect of healthy eosinophils. Real-time quantitative PCR analysis revealed significantly increased mRNA levels of the immunoregulatory protein galectin-10 in the eosinophils of both chronic GVHD patients and patients without GVHD, as compared with those from healthy subjects. The upregulation of galectin-10 expression in eosinophils from patients suggests a stimulatory effect of HSC transplantation in itself on eosinophilic galectin-10 expression, regardless of chronic GVHD status. To conclude, eosinophils from HSC transplant recipients and healthy subjects have a T cell suppressive capacity.
Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Eosinophil; Galectin-10; Graft-versus-host disease; Suppression; T cell inflammation

Mesh:

Substances:

Year:  2014        PMID: 25175795     DOI: 10.1016/j.bbmt.2014.08.017

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  4 in total

1.  Eosinophils from eosinophilic oesophagitis patients have T cell suppressive capacity and express FOXP3.

Authors:  C Lingblom; J Wallander; M Ingelsten; H Bergquist; M Bove; R Saalman; A Welin; C Wennerås
Journal:  Clin Exp Immunol       Date:  2016-12-06       Impact factor: 4.330

2.  Eosinophilia during letermovir treatment after allogeneic hematopoietic stem cell transplantation.

Authors:  Hiroki Hosoi; Shogo Murata; Toshiki Mushino; Akinori Nishikawa; Takashi Sonoki
Journal:  Ann Hematol       Date:  2020-08-21       Impact factor: 3.673

3.  Activation of group 2 innate lymphoid cells alleviates aging-associated cognitive decline.

Authors:  Ivan Ting Hin Fung; Poornima Sankar; Yuanyue Zhang; Lisa S Robison; Xiuli Zhao; Shanti S D'Souza; Abigail E Salinero; Yue Wang; Jiang Qian; Marcy L Kuentzel; Sridar V Chittur; Sally Temple; Kristen L Zuloaga; Qi Yang
Journal:  J Exp Med       Date:  2020-04-06       Impact factor: 14.307

4.  Kinetic studies of galectin-10 release from eosinophils exposed to proliferating T cells.

Authors:  C Lingblom; K Andersson; C Wennerås
Journal:  Clin Exp Immunol       Date:  2020-11-17       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.